GlassScriptPhysician profile
Dawn Harbatkin
NPI 1033119284
$6,440.49
in general payments reported to CMS, 2019-2025
31 companies · $847 in 2025
The $847 reported for 2025 was more than what 93% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
See the full distribution for Addiction Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.03 · 2023: $473 · 2024: $5,052 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Consulting Fee: $1,938 · Travel and Lodging: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,344.27 |
| Consulting Fee | $1,938.00 |
| Travel and Lodging | $1,090.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,374.42 | 2019-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $491.40 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $378.61 | 2023-2024 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.36 | 2023-2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $247.25 | 2023-2024 | Quviviq |
| Lundbeck LLC | $207.27 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $175.23 | 2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $153.24 | 2024-2025 | Hyqvia, Trintellix |
| Alkermes, INC. | $122.14 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $119.89 | 2023-2024 | Fanapt, Hetlioz |
| Braeburn INC. | $117.12 | 2025 | Brixadi |
| Axsome Therapeutics, INC. | $110.60 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $108.51 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $96.21 | 2024-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $79.10 | 2025 | Wainua |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $67.28 | 2024-2025 | Gamunex-C |
| Averitas Pharma INC. | $34.06 | 2025 | Qutenza |
| Noven Therapeutics, LLC | $33.94 | 2024 | Secuado, Xelstrym |
| Emd Serono, INC. | $32.60 | 2025 | |
| Corium, LLC | $26.62 | 2023 | Adlarity |
| Itf Therapeutics LLC | $26.41 | 2025 | |
| Eisai INC. | $21.65 | 2025 | |
| Tanabe Pharma America, INC. | $21.32 | 2025 | Radicava |
| Biogen, INC. | $20.64 | 2025 | Skyclarys |
| Catalyst Pharmaceuticals, INC. | $18.11 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.78 | 2025 | Ongentys |
| Azurity Pharmaceuticals, INC. | $17.09 | 2023 | Horizant |
| Octapharma USA, INC. | $16.86 | 2025 | Panzyga |
| Alexion Pharmaceuticals, INC. | $16.09 | 2025 | Ultomiris |
| Ucb, INC. | $14.69 | 2025 | Rystiggo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,048.70 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Harbatkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.